O CHANGE WAS DE LA COLOR OF THE PARTY OF THE

DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center – WO66-0609 Silver Spring, MD 20993-0002

JUL 1 9 2010

Bennett Greenspan
President and CEO, Family Tree DNA
DNATraits
1445 North Loop West, Suite 820
Houston, TX 77008

Dear Mr. Greenspan:

It has come to our attention that you are currently marketing the Ashkenazi Jews Genetic Disease Panel, a home-use device that is intended for Jews of Ashkenazi descent to identify their carrier status for 25 hereditary diseases, including Tay-Sachs, Cystic Fibrosis, Gaucher Disease, and others. The Ashkenazi Jews Genetic Disease Panel appears to meet the definition of a device as that term is defined in section 201(h) of the Federal Food Drug and Cosmetic Act.

We have conducted a review of our files, and have been unable to identify any Food and Drug Administration (FDA) clearance or approval number for Ashkenazi Jews Genetic Disease Panel. We request that you provide us with the FDA clearance or approval number for the Ashkenazi Jews Genetic Disease Panel. If you do not believe that you are required to obtain FDA clearance or approval for the Ashkenazi Jews Genetic Disease Panel, please provide us with the basis for that determination.

If you would like to meet with us to discuss whether there are tests you are promoting that do not require review by FDA and what information you would need to submit in order for your product to be legally marketed, let us know and we will schedule a meeting with you. Please direct your questions and response to:

James L. Woods
Deputy Director, Patient Safety and Product Quality
Office of *In Vitro* Diagnostic Device Evaluation and Safety
10903 New Hampshire Avenue
White Oak 66
Silver Spring, MD 20993

We would appreciate a response within 15 days from the date of this letter. If you have any questions relating to this matter, please feel free to call Joshua Levin at 301-796-

6695, or access our website at http://www.fda.gov for general information relating to FDA's device requirements.

Sincerely yours,

James Woods
Deputy Director

Patient Safety and Product Quality
Office of In Vitro Diagnostic

Device Evaluation and Safety

Center for Devices and Radiological Health